NCT05806294Completed
Digital Metabolic Rehabilitation COPD
Utilizing Canadian Digital Technology to Prevent and Manage Diabetes, Obesity, and Heart Disease in Patients Living With Congestive Obstructive Pulmonary Disease - A Single-arm Pilot Study
Source: ClinicalTrials.gov · Last updated 3 Apr 2025
Brief summary (registry, in English)
People with Chronic Obstructive Pulmonary Disease (COPD) are at greater risk for Metabolic syndrome (MetS). Although the management of MetS will not cure COPD, it can beneficially impact health outcomes and quality of life through lifestyle modifications. The study aims to determine if using the Digital Metabolic Rehab program, which is based on preventive self-care and includes three key pillars of health: nutrition, fitness, and mindfulness, will be feasible to reduce or reverse MetS for individuals living with COPD.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 3 Mar 2023
- Start date
- 17 Nov 2022
- Primary completion date
- 15 Jul 2024
- Lead sponsor
- University of Alberta
- NCT number
- NCT05806294
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 17 Nov 2022 to the primary completion date, 15 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Having a medical or physical condition that makes moderate-intensity physical difficult or unsafe
- Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), COPD stages 3 or 4, heart failure stage D, stroke, and ongoing substance abuse, undergoing active treatment for cancer
- Diagnosis of psychiatric disorders that would limit the adequate ability to comply with the study protocol
Lab values
- Diagnosis of Type 1 diabetes mellitus or type 2 diabetes mellitus with proliferative diabetic retinopathy, nephropathy (serum creatine \> 160 µmol/L), clinically significant neuropathy (defined as absent ankle jerks), severe hyperglycemia (fasting blood glucose \> 11 mmol/L), or claudication symptoms
- Clinically significant renal failure (.i.e., creatinine \> 200 µmol/L)
Other
- Inability to speak, read or understand English
- Unable or unwilling to use technology to meet with the healthcare team and My Viva Plan to manage self-care
Who the study is looking for
- Adult patients (18+)
- COPD stage 1 or 2
- Identified by their family doctor as having at least two out of five MetS factors
- Adjusted body mass index (BMI) between 26 to 40
- Able to provide written informed consent in English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.